Roivant Sciences: Venker proposes $7.02M share sale

His prior-three-month sales included 200,000 shares on July 27, 13,909 on August 20, 200,000 on August 28 and 200,000 on September 30, 2026.

Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) reports that its officer, Eric Venker, gave notice of a proposed sale of 200,000 common shares, with an aggregate market value of $7,023,513.39. The approximate sale date is October 20, 2026, through Rockefeller Financial LLC on NASDAQ. The sale is pursuant to a Rule 10b5-1 trading plan adopted by Venker on June 30, 2026.

Key Figures

Shares in proposed sale: 200,000 shares Aggregate market value: $7,023,513.39 Reported sale: 200,000 shares; $6,989,924.05 gross proceeds +3 more

6 metrics

Shares in proposed sale 200,000 shares Proposed common-share sale

Aggregate market value $7,023,513.39 Proposed common-share sale

Reported sale 200,000 shares; $6,989,924.05 gross proceeds July 27, 2026

Reported sale 13,909 shares; $512,407.56 gross proceeds August 20, 2026

Reported sale 200,000 shares; $7,147,087.91 gross proceeds August 28, 2026

Reported sale 200,000 shares; $7,323,556.00 gross proceeds September 30, 2026

Key Terms

Rule 10b5-1 trading plan, RSU Grant, Rule 144

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

RSU Grant financial

"RSU Grant 019326 - Grant Date 04/20/2022"

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ROIV shares does Eric Venker plan to sell?

Venker reported a proposed sale of 200,000 common shares, with an aggregate market value of $7,023,513.39. The approximate sale date is October 20, 2026, through Rockefeller Financial LLC on NASDAQ. The sale is pursuant to a Rule 10b5-1 trading plan adopted June 30, 2026.

What previous ROIV share sales did Eric Venker report?

For the prior three months, Venker reported sales of 200,000 shares for $6,989,924.05 on July 27, 2026; 13,909 shares for $512,407.56 on August 20; 200,000 shares for $7,147,087.91 on August 28; and 200,000 shares for $7,323,556.00 on September 30.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/20/2026 - 04:45 PM EDT Accepted by SEC EDGAR 10/20/2026 - 04:44 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001801917
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Roivant Sciences Ltd.
SEC File Number	001-40782
Address of Issuer	7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM SW1H 0DB
Phone	441-295-5950
Name of Person for Whose Account the Securities are To Be Sold	Venker Eric
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111	200000	7023513.39	722323015	10/20/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	03/24/2025	RSU Grant 019326 - Grant Date 04/20/2022	Roivant Sciences Ltd.			153810	03/24/2025	N/A
Common Shares	04/20/2025	RSU Grant 018861 - Grant Date 05/20/2021	Roivant Sciences Ltd.			8847	04/20/2025	N/A
Common Shares	05/20/2025	RSU Grant 020409 - Grant Date 07/26/2024	Roivant Sciences Ltd.			22797	05/20/2025	N/A
Common Shares	05/20/2025	RSU Grant 018861 - Grant Date 05/20/2021	Roivant Sciences Ltd.			8847	05/20/2025	N/A
Common Shares	08/20/2025	RSU Grant 020409 - Grant Date 07/26/2024	Roivant Sciences Ltd.			5699	08/20/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway London X0 SW1H0DB	Common Shares	07/27/2026	200000	6989924.05
Eeric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H0DB	Common Shares	08/20/2026	13909	512407.56
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H0DB	Common Shares	08/28/2026	200000	7147087.91
Eric Venker c/o Roivant Sciences Ltd 7th Floor, 50 Broadway London X0 X0 SW1H0DB	Common Shares	09/30/2026	200000	7323556.00

144: Remarks and Signature

Remarks	The shares reported on this Form 144 will be sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 06/30/2026.
Date of Notice	10/20/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/30/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Daniel Gardea as a duly authorized representative of National Financial Services LLC, as attorney-in-fact for Eric Venker
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)